Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
Features include: Acute monocytic leukemia.
Biomarker and diagnostic research for acute monocytic leukemia has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
13 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 6 PHASE2, 3 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03670966](https://clinicaltrials.gov/study/NCT03670966) | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | PHASE1 | Fred Hutchinson Cancer Center | RECRUITING |
[NCT05566054](https://clinicaltrials.gov/study/NCT05566054) | Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia | PHASE2 | The First Affiliated Hospital of Soochow University | RECRUITING |
[NCT03964506](https://clinicaltrials.gov/study/NCT03964506) | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | EARLY_PHASE1 | Omar Aljitawi | RECRUITING |
[NCT06950034](https://clinicaltrials.gov/study/NCT06950034) | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | PHASE1 | Solu Therapeutics, Inc | RECRUITING |
[NCT07512700](https://clinicaltrials.gov/study/NCT07512700) | Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia | PHASE2 | Chinese PLA General Hospital | RECRUITING |
179 publications have been identified in PubMed for acute monocytic leukemia. Kisho has analyzed 97 by research type. Research spans Basic Science / Preclinical (62%), Case Report / Case Series (25%), and Gene Therapy / Novel Therapeutics (7%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 60 | 62% |
Patient case studies | 24 | 25% |
New treatment approaches | 7 | 7% |
Disease patterns and progression | 3 | 3% |
Testing and diagnosis research | 2 | 2% |
Clinical study results | 1 |
Huang F (2026). [PMID: 40590394](https://pubmed.ncbi.nlm.nih.gov/40590394/). *Cell proliferation*. [Diagnostic / Biomarker]
Chen J (2026). [PMID: 41621473](https://pubmed.ncbi.nlm.nih.gov/41621473/). *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. [Case Report / Case Series]
Huang W (2026). [PMID: 41585174](https://pubmed.ncbi.nlm.nih.gov/41585174/). *Journal of dental sciences*. [Gene Therapy / Novel Therapeutics]
Liu T (2026). [PMID: 41205385](https://pubmed.ncbi.nlm.nih.gov/41205385/). *International immunopharmacology*. [Basic Science / Preclinical]
Pan T (2026). [PMID: 41435748](https://pubmed.ncbi.nlm.nih.gov/41435748/). *Biochemical and biophysical research communications*. [Basic Science / Preclinical]
Yu L (2026). [PMID: 41753590](https://pubmed.ncbi.nlm.nih.gov/41753590/). *Microorganisms*. [Basic Science / Preclinical]
Amatya C (2026). [PMID: 41702648](https://pubmed.ncbi.nlm.nih.gov/41702648/). *Journal for immunotherapy of cancer*. [Basic Science / Preclinical]
Li Y (2026). [PMID: 41704870](https://pubmed.ncbi.nlm.nih.gov/41704870/). *Biochemistry research international*. [Basic Science / Preclinical]
Batsi Y (2026). [PMID: 41135285](https://pubmed.ncbi.nlm.nih.gov/41135285/). *Bioorganic & medicinal chemistry*. [Basic Science / Preclinical]
Geng B (2026). [PMID: 41536519](https://pubmed.ncbi.nlm.nih.gov/41536519/). *MedComm*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 4:32 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute monocytic leukemia